CLINICAL STUDIES
Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
Antonino Buffon, MDa,
Giovanna Liuzzo, MDa,
Luigi M. Biasucci, MD, FACCa,
Patrizio Pasqualetti, PhD*,
Vito Ramazzotti, MDa,
Antonio G. Rebuzzi, MDa,
Filippo Crea, MD, FACCa and
Attilio Maseri, MD, FACCa
a Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
* A.Fa.R., Ospedale Fetebenefratelli-Isola Tiberina, Rome, Italy
Manuscript received October 1, 1998;
revised manuscript received March 25, 1999,
accepted June 28, 1999.
Reprint requests and correspondence: Dr. Antonino Buffon, Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Largo Gemelli, 8 - 00168 Rome, Italy. abuffon{at}mail.OMNITEL.IT
OBJECTIVES
We sought to investigate whether early and late outcome after percutaneous transluminal coronary angioplasty (PTCA) could be predicted by baseline levels of acute-phase reactants.
BACKGROUND
Although some risk factors for acute complications and restenosis have been identified, an accurate preprocedural risk stratification of patients undergoing PTCA is still lacking.
METHODS
Levels of C-reactive protein (CRP), serum amyloid A protein (SAA) and fibrinogen were measured in 52 stable angina and 69 unstable angina patients undergoing single vessel PTCA.
RESULTS
Tertiles of CRP levels (relative risk [RR] = 12.2, p < 0.001), systemic hypertension (RR = 4.3, p = 0.046) and female gender (RR = 4.1, p = 0.033) were the only independent predictors of early adverse events. Intraprocedural and in-hospital complications were observed in 22% of 69 patients with high serum levels (>0.3 mg/dl) of CRP and in none of 52 patients with normal CRP levels (p < 0.001). Tertiles of CRP levels (RR = 6.2, p = 0.001), SAA levels (RR = 6.0, p = 0.011), residual stenosis (RR = 3.2, p = 0.007) and acute gain (RR = 0.3, p = 0.01) were the only independent predictors of clinical restenosis. At one-year follow-up, clinical restenosis developed in 63% of patients with high CRP levels and in 27% of those with normal CRP levels (p < 0.001).
CONCLUSIONS
Preprocedural CRP level, an easily measurable marker of acute phase response, is a powerful predictor of both early and late outcome in patients undergoing single vessel PTCA, suggesting that early complications and clinical restenosis are markedly influenced by the preprocedural degree of inflammatory cell activation.
|
Abbreviations and Acronyms
| | CABG | = coronary bypass graft surgery | | CI | = confidence interval | | CRP | = C-reactive protein | | ECG | = electrocardiogram | | MI | = myocardial infarction | | PTCA | = percutaneous transluminal coronary angioplasty | | RR | = relative risk | | SAA | = serum amyloid A protein | | TIMI | = Thrombolysis in Myocardial Infarction |
|
This article has been cited by other articles:

|
 |

|
 |
 
D. Tousoulis, N. Papageorgiou, and C. Stefanadis
Is C-reactive protein a prognostic marker after angioplasty?
Heart,
June 15, 2009;
95(12):
957 - 959.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W C Kang, T H Ahn, C I Moon, S H Han, E K Shin, J-S Kim, Y-G Ko, D Choi, Y Jang, B-K Kim, et al.
Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents
Heart,
June 15, 2009;
95(12):
970 - 975.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Iijima, R A Byrne, G Ndrepepa, S Braun, J Mehilli, P B Berger, A Schomig, and A Kastrati
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials
Heart,
January 15, 2009;
95(2):
107 - 112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon
Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
137 - 146.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, M. Szarek, D. D. Waters, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress
Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study
Arterioscler Thromb Vasc Biol,
January 1, 2008;
28(1):
142 - 147.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Groschel, U. Ernemann, J. Larsen, M. Knauth, F. Schmidt, J. Artschwager, and A. Kastrup
Preprocedural C-Reactive Protein Levels Predict Stroke and Death in Patients Undergoing Carotid Stenting
AJNR Am. J. Neuroradiol.,
October 1, 2007;
28(9):
1743 - 1746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. G. Hage and A. J. Szalai
C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk
J. Am. Coll. Cardiol.,
September 18, 2007;
50(12):
1115 - 1122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.-W. Park, C. W. Lee, S.-C. Yun, Y.-H. Kim, M.-K. Hong, J.-J. Kim, S.-W. Park, and S.-J. Park
Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation
Heart,
September 1, 2007;
93(9):
1087 - 1092.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
Vascular Medicine,
May 1, 2007;
12(2):
113 - 122.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Palmerini, A. Marzocchi, C. Marrozzini, L. B. Reggiani, C. Savini, G. Marinelli, R. Di Bartolomeo, and A. Branzi
Preoperative C-reactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis
Eur. J. Cardiothorac. Surg.,
April 1, 2007;
31(4):
685 - 690.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Assmus, D. H. Walter, R. Lehmann, J. Honold, H. Martin, S. Dimmeler, A. M. Zeiher, and V. Schachinger
Intracoronary infusion of progenitor cells is not associated with aggravated restenosis development or atherosclerotic disease progression in patients with acute myocardial infarction
Eur. Heart J.,
December 2, 2006;
27(24):
2989 - 2995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease
Diabetes,
March 1, 2006;
55(3):
780 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Pascual, J. M. Arribas, P. L. Tornel, F. Marin, C. Oliver, M. Ahumada, J. Gomez-Plana, P. Martinez, R. Arcas, and M. Valdes
Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery
Ann. Thorac. Surg.,
January 1, 2006;
81(1):
78 - 83.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J.,
December 1, 2005;
26(23):
2493 - 2519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Saleh, B. Svane, L.-O. Hansson, J. Jensen, T. Nilsson, O. Danielsson, and P. Tornvall
Response of Serum C-Reactive Protein to Percutaneous Coronary Intervention Has Prognostic Value
Clin. Chem.,
November 1, 2005;
51(11):
2124 - 2130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Park
Inflammatory Biomarkers for Prediction of Outcomes After Unprotected Left Main Coronary Intervention
Circulation,
October 11, 2005;
112(15):
2226 - 2227.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Palmerini, A. Marzocchi, C. Marrozzini, P. Ortolani, F. Saia, L. Bacchi-Reggiani, S. Virzi, S. Gianstefani, and A. Branzi
Preprocedural Levels of C-Reactive Protein and Leukocyte Counts Predict 9-Month Mortality After Coronary Angioplasty for the Treatment of Unprotected Left Main Coronary Artery Stenosis
Circulation,
October 11, 2005;
112(15):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L M Biasucci, G Giubilato, F Graziani, and M Piro
CRP is or is not a reliable marker of ischaemic heart disease?
Lupus,
September 1, 2005;
14(9):
752 - 755.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Biasucci
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper
Circulation,
December 21, 2004;
110(25):
e560 - e567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Toutouzas, A. Colombo, and C. Stefanadis
Inflammation and restenosis after percutaneous coronary interventions
Eur. Heart J.,
October 1, 2004;
25(19):
1679 - 1687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Morrow
Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A US Perspective
Clin. Chem.,
September 1, 2004;
50(9):
1489 - 1491.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Biasucci and G. G.L. Biondi-Zoccai
Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A European Perspective
Clin. Chem.,
September 1, 2004;
50(9):
1492 - 1494.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Z.H. Rittersma, R. J. de Winter, K. T. Koch, C. E. Schotborgh, M. Bax, G. S. Heyde, J. P. van Straalen, K. J. Mulder, J. G.P. Tijssen, G. T. Sanders, et al.
Preprocedural C-Reactive Protein Is Not Associated with Angiographic Restenosis or Target Lesion Revascularization after Coronary Artery Stent Placement
Clin. Chem.,
September 1, 2004;
50(9):
1589 - 1596.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Blaschke, D. Bruemmer, F. Yin, Y. Takata, W. Wang, M. C. Fishbein, T. Okura, J. Higaki, K. Graf, E. Fleck, et al.
C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells
Circulation,
August 3, 2004;
110(5):
579 - 587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Segev, S. Kassam, C. E Buller, H. K Lau, J. D Sparkes, P. W Connelly, P. H Seidelin, M. K Natarajan, E. A Cohen, and B. H Strauss
Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting
Eur. Heart J.,
June 2, 2004;
25(12):
1029 - 1035.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M N Zairis, J A Ambrose, A G Lyras, M A Thoma, P K Psarogianni, P G Psaltiras, A D Kardoulas, G P Bibis, E G Pissimissis, P C Batika, et al.
C Reactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: four year results from the GENERATION study
Heart,
April 1, 2004;
90(4):
419 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M Backes, P. A Howard, and P. M Moriarty
Role of C-Reactive Protein in Cardiovascular Disease
Ann. Pharmacother.,
January 1, 2004;
38(1):
110 - 118.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. Danenberg, G. Golomb, A. Groothuis, J. Gao, H. Epstein, R. V. Swaminathan, P. Seifert, and E. R. Edelman
Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits
Circulation,
December 2, 2003;
108(22):
2798 - 2804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Cipollone, C. Ferri, G. Desideri, L. Paloscia, G. Materazzo, M. Mascellanti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, et al.
Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty
Circulation,
December 2, 2003;
108(22):
2776 - 2782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Biancari, J. Lahtinen, S. Lepojarvi, P. Rainio, E. Salmela, R. Pokela, M. Lepojarvi, J. Satta, and T. S. Juvonen
Preoperative C-reactive protein and outcome after coronary artery bypass surgery
Ann. Thorac. Surg.,
December 1, 2003;
76(6):
2007 - 2012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Verma, M. V. Badiwala, R. D. Weisel, S.-H. Li, C.-H. Wang, P. W. M. Fedak, R.-K. Li, and D. A. G. Mickle
C-reactive protein activates the nuclear factor-{kappa}B signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis
J. Thorac. Cardiovasc. Surg.,
December 1, 2003;
126(6):
1886 - 1891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M Ridker and on behalf of the JUPITER Study Group
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*
Circulation,
November 11, 2003;
108(19):
2292 - 2297.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-M. Lu, Y.-A. Ding, S.-J. Lin, W.-S. Lee, and H.-C. Tai
Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention
Eur. Heart J.,
November 1, 2003;
24(21):
1912 - 1919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.M. Hirschfield and M.B. Pepys
C-reactive protein and cardiovascular disease: new insights from an old molecule
QJM,
November 1, 2003;
96(11):
793 - 807.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Rahel, F. L.J. Visseren, M.-J. Suttorp, T. H.W. Plokker, J. C. Kelder, B. M. de Jongh, K.P. Bouter, and R. J.A. Diepersloot
Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention
Cardiovasc Res,
October 15, 2003;
60(1):
136 - 140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H S Gurm, D L Bhatt, A M Lincoff, J E Tcheng, D J Kereiakes, N S Kleiman, G Jia, and E J Topol
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
Heart,
October 1, 2003;
89(10):
1200 - 1204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Dee and H. Samady
Evolving Strategies for the Prevention and Treatment of Coronary Restenosis
Seminars in Cardiothoracic and Vascular Anesthesia,
September 1, 2003;
7(3):
281 - 293.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
F Cipollone, M Fazia, A Iezzi, B Pini, F Costantini, D De Cesare, L Paloscia, G Materazzo, E D'Annunzio, T Bucciarelli, et al.
High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis
Heart,
July 1, 2003;
89(7):
773 - 779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schillinger, M. Exner, W. Mlekusch, M. Haumer, H. Rumpold, R. Ahmadi, S. Sabeti, O. Wagner, and E. Minar
Endovascular Revascularization Below the Knee: 6-month Results and Predictive Value of C-reactive Protein Level
Radiology,
May 1, 2003;
227(2):
419 - 425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Chan, D. L. Bhatt, D. P. Chew, J. Reginelli, J. P. Schneider, E. J. Topol, and S. G. Ellis
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Circulation,
April 8, 2003;
107(13):
1750 - 1756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. G. L. Biondi-Zoccai, A. Abbate, G. Liuzzo, and L. M. Biasucci
Atherothrombosis, inflammation, and diabetes
J. Am. Coll. Cardiol.,
April 2, 2003;
41(7):
1071 - 1077.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Zimmerman, C. H. Selzman, C. Cothren, A. C. Sorensen, C. D. Raeburn, and A. H. Harken
Diagnostic Implications of C-Reactive Protein
Arch Surg,
February 1, 2003;
138(2):
220 - 224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T Lenderink, E Boersma, C Heeschen, A Vahanian, M.-J de Boer, V Umans, M.J.B.M van den Brand, C.W Hamm, M.L Simoons, and for the CAPTURE investigators
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA
Eur. Heart J.,
January 1, 2003;
24(1):
77 - 85.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Versaci, A. Gaspardone, F. Tomai, F. Ribichini, P. Russo, I. Proietti, A. S. Ghini, V. Ferrero, L. Chiariello, P. Agostino Gioffre, et al.
Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study)
J. Am. Coll. Cardiol.,
December 4, 2002;
40(11):
1935 - 1942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann, A. Lerman, D. Baumgart, L. Volbracht, R. Schulz, C. von Birgelen, M. Haude, G. Heusch, and R. Erbel
Preprocedural Statin Medication Reduces the Extent of Periprocedural Non-Q-Wave Myocardial Infarction
Circulation,
October 22, 2002;
106(17):
2180 - 2183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Zairis, J. A. Ambrose, S. J. Manousakis, A. S. Stefanidis, O. A. Papadaki, H. I. Bilianou, M. C. DeVoe, C. N. Fakiolas, E. G. Pissimissis, C. D. Olympios, et al.
The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The global evaluation of new events and restenosis after stent implantation study
J. Am. Coll. Cardiol.,
October 16, 2002;
40(8):
1375 - 1382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schillinger, M. Exner, W. Mlekusch, H. Rumpold, R. Ahmadi, S. Sabeti, M. Haumer, O. Wagner, and E. Minar
Vascular Inflammation and Percutaneous Transluminal Angioplasty of the Femoropopliteal Artery: Association with Restenosis
Radiology,
October 1, 2002;
225(1):
21 - 26.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schillinger, M. Exner, W. Mlekusch, M. Haumer, R. Ahmadi, H. Rumpold, O. Wagner, and E. Minar
Inflammatory Response to Stent Implantation: Differences in Femoropopliteal, Iliac, and Carotid Arteries
Radiology,
August 1, 2002;
224(2):
529 - 535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Bhatt and E. J. Topol
Need to Test the Arterial Inflammation Hypothesis
Circulation,
July 2, 2002;
106(1):
136 - 140.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. Danenberg, F. G. P. Welt, M. Walker III, P. Seifert, G. S. Toegel, and E. R. Edelman
Systemic Inflammation Induced by Lipopolysaccharide Increases Neointimal Formation After Balloon and Stent Injury in Rabbits
Circulation,
June 18, 2002;
105(24):
2917 - 2922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.J. de Winter, G.S. Heyde, K.T. Koch, J. Fischer, J.P. van Straalen, M. Bax, C.E. Schotborgh, K.J. Mulder, G.T. Sanders, J.J. Piek, et al.
The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty
Eur. Heart J.,
June 2, 2002;
23(12):
960 - 966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Walter, S. Fichtlscherer, M. B. Britten, P. Rosin, W. Auch-Schwelk, V. Schachinger, and A. M. Zeiher
Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation
J. Am. Coll. Cardiol.,
December 1, 2001;
38(7):
2006 - 2012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein
Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy
Eur. Heart J.,
November 2, 2001;
22(22):
2058 - 2074.
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Blake and P. M. Ridker
Novel Clinical Markers of Vascular Wall Inflammation
Circ. Res.,
October 26, 2001;
89(9):
763 - 771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Gum, M. Thamilarasan, J. Watanabe, E. H. Blackstone, and M. S. Lauer
Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease: A Propensity Analysis
JAMA,
September 12, 2001;
286(10):
1187 - 1194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Chew, D. L. Bhatt, M. A. Robbins, M. S. Penn, J. P. Schneider, M. S. Lauer, E. J. Topol, and S. G. Ellis
Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention
Circulation,
August 28, 2001;
104(9):
992 - 997.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Lincoff, D. J. Kereiakes, M. A. Mascelli, L. I. Deckelbaum, E. S. Barnathan, K. K. Patel, B. Frederick, M. T. Nakada, and E. J. Topol
Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization
Circulation,
July 10, 2001;
104(2):
163 - 167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Walter, S. Fichtlscherer, M. Sellwig, W. Auch-Schwelk, V. Schachinger, and A. M. Zeiher
Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation
J. Am. Coll. Cardiol.,
March 1, 2001;
37(3):
839 - 846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. B Pepys and A. Berger
The renaissance of C reactive protein
BMJ,
January 6, 2001;
322(7277):
4 - 5.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Wijns and F. Ribichini
CRP: does it stand for C oronary R estenosis P rediction?
Eur. Heart J.,
July 2, 2000;
21(14):
1121 - 1123.
[PDF]
|
 |
|

|
 |

|
 |
 
E. Rossi, L. M. Biasucci, F. Citterio, S. Pelliccioni, C. Monaco, F. Ginnetti, D. J. Angiolillo, G. Grieco, G. Liuzzo, and A. Maseri
Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease: Predictive Role of C-Reactive Protein
Circulation,
February 19, 2002;
105(7):
800 - 803.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|